This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Cardiovascular/ Cardiothoracic Surgery  • Prognosis/ Outcomes  • Revascularization  • Alert me on articles by topic

Irving L. Kron, MD

Arch Surg. 2006;141:642.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Moretti and colleagues from Duke University have demonstrated that preoperative levels of EndoCAb are associated with increased long-term mortality after CABG surgery using CPB. This is truly a unique finding and worthy of further discussion. Essentially, this finding implies that increased EndoCAb levels carry increased short- and long-term risks after CABG surgery. Although the findings are statistically significant, I’m not sure I understand the logic of this finding. We don't know why the patients died in either subgroup, so it is difficult to explain the increased long-term mortality based on potential increases in EndoCAb levels. In addition, it does not seem that the authors have excluded 30- or 60-day mortality from the analysis.

The authors explained in their discussion their thoughts about this association. They stated that low EndoCAb levels may potentially be a marker for increased operative risk. Although they used the Parsonnet additive risk . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED ARTICLE

Effects of Decreased Preoperative Endotoxin Core Antibody Levels on Long-term Mortality After Coronary Artery Bypass Graft Surgery
Eugene W. Moretti, Mark F. Newman, Lawrence H. Muhlbaier, David Whellan, Rebecca P. Petersen, Daniel Rossignol, Charles B. McCants, Jr, Barbara Phillips-Bute, and Elliott Bennett-Guerrero
Arch Surg. 2006;141(7):637-641.
ABSTRACT | FULL TEXT